LimFlow Completes Enrollment In US Feasibility Study and Receives Breakthrough Device Status from FDA for Its Percutaneous Deep Vein Arterialization (pDVA) System
LimFlow Completes Enrollment In US Feasibility Study and Receives Breakthrough Device Status from FDA for Its Percutaneous Deep Vein Arterialization (pDVA) System
Previous PostLimFlow Nominates Pierre Guyot as Chairman of Board of Directors and Expands Senior Management Team
Next PostGecko Biomedical secures €6 million in funding under the Investments for the Future program, to industralize and develop innovative solutions for tissue reconstruction
